Concurrent chemoradiotherapy with paclitaxel and carboplatin for stage III or IVA cervical cancer with renal dysfunction

Concurrent chemoradiotherapy with paclitaxel and carboplatin for stage III or IVA cervical cancer with renal dysfunction - CCRT with TC for cervical cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026034

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced stage III or IVA cervical cancer with renal dysfunction

Interventions

Radiotherapy and chemotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients diagnosed stage III or IVA cervical cancer with renal dysfunction (eGFR is less than 60)

Exclusion criteria

Exclusion criteria: Patients treated with paclitaxel or carboplatin previously

Design outcomes

Primary

Measure	Time frame
Cancellation rate by adverse events	—

Countries

Japan

Contacts

Public ContactYuichi Imai

Yokohama City University Hospital Department of Obstetrics and gynecology

you11sep@gmail.com045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026